Article ID Journal Published Year Pages File Type
1086783 Le Pharmacien Hospitalier et Clinicien 2015 10 Pages PDF
Abstract
From an analytical point of view, rate of analysis is satisfactory but the main limit of the method is the identification of the active substance only by its UV-visible spectral properties. So, discrimination between some drugs is not possible, i.e. for ifosfamide/cyclophosphamide, or vindesine/vinblastine or doxorubicine/daunorubicine. Moreover, monoclonal antibodies preparations cannot be analysed by FIA-DAD. Other devices available on the market (Multispec®, RXN1 analyser®, QcPrep) can compensate for these inadequacies but the investment is relatively expensive and can act as an obstacle to the control. In fact, new practices have to be considered.
Keywords
Related Topics
Health Sciences Pharmacology, Toxicology and Pharmaceutical Science Pharmacology, Toxicology and Pharmaceutics (General)
Authors
, , , , , ,